Tens of thousands of Britons have been advised to discontinue the use of the fat-busting drug Reductil after the Medicines and Healthcare Products Regulatory Agency (MHRA)’s recent decision to suspend its licence. The announcement came after the European Medicines Agency (EMA) assessed the drug and recommended the suspension of its licence in Europe where they found an increased risk of heart attacks and strokes, over a six-year period after tests, in which 16 percent of 10,000 patients who took it showed an increase.

In 2009 nearly 86,000 Britons to the weight loss drug which alters the brain’s chemical messages that control a person’s craving for food. Many experts say although threatens the health of the obese, its side-effects are mostly not fatal. Dr June Raine, of the MHRA, said: “Evidence suggests that there is an increased risk of non-fatal heart attacks and strokes with this medicine that outweigh the benefits of weight loss, which is modest and may not be sustained in the long term after stopping treatment.”

UK doctors have been asked to stop prescribing the drug and review its use in patients who are already taking it although the Reductil licence suspension decision by the UK regulator still requires a formal sanction by the European Commission. There are other weight loss drugs available like Xenical which are just as effective, which stops the absorption of fat and controls fat intake.